REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- FRUTAROM
- GAZIT GLOBE
- HAREL
- ICL
- ISRAEL CORP
- LEUMI
- MAZOR ROBOTICS
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- POALIM
- SHUFERSAL
- SODASTREAM
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2018.10.26 | 07:15 | Permanent Information Releases / General Company News

puce Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis - HTML (w)

2018.10.23 | 07:15 | Permanent Information Releases / General Company News

puce Alcon to develop SMART Suite digital health platform for cataract surgery - HTML (w)

2018.10.23 | 00:30 | Permanent Information Releases / General Company News

puce Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed - HTML (w)

2018.10.22 | 09:15 | Permanent Information Releases / General Company News

puce Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma - HTML (w)

2018.10.20 | 16:30 | Permanent Information Releases / General Company News

puce Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone - HTML (w)

2018.10.19 | 16:00 | Permanent Information Releases / General Company News

puce Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC - HTML (w)

2018.10.19 | 07:15 | Permanent Information Releases / General Company News

puce Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden - HTML (w)

2018.10.18 | 07:02 | Permanent Information Releases / General Company News

puce Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms - HTML (w)

2018.10.18 | 07:00 | Permanent Information Releases / General Company News

puce Novartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittlicheTherapieplattformen voran, um das zukünftige Wachstum zu beschleunigen - HTML (w)

2018.10.18 | 07:00 | Periodic information / 3rd Quarter Information

puce Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth - HTML (w)

2018.10.18 | 07:00 | Periodic information / 3rd Quarter Information

puce Novartis a enregistré, au troisième trimestre, une forte croissance et fait preuve d'une innovation dynamique, incluant des plateformes thérapeutiques avancées pour soutenir la croissance future - HTML (w)

2018.10.16 | 07:15 | Permanent Information Releases / General Company News

puce Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis - HTML (w)

2018.10.11 | 22:35 | Permanent Information Releases / General Company News

puce Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access - HTML (w)

2018.10.10 | 22:30 | Permanent Information Releases / General Company News

puce Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis - HTML (w)

2018.10.10 | 07:15 | Permanent Information Releases / General Company News

puce Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1140